Connect with us

Technology

Replenish Nutrients Announces Strategic Relationship with SRC Agrominerals, including $15 Million Strategic Investment, Beiseker Facility Expansion and Supply Agreement

Published

on

OKOTOKS, AB, July 20, 2026 /CNW/ — Replenish Nutrients Holding Corp. (CSE: ERTH) (OTC: VVIVF) (“Replenish” or the “Company”) is pleased to announce that it has entered into a securities purchase agreement (the “Investment Agreement”) dated July 17, 2026 with SRC Agrominerals (“SRC”) to support and accelerate Replenish’s near-term growth, including an expansion of the Beiseker facility (the “Beiseker Pelletization Expansion”). Additionally, Mr. Tim Close, the CEO of SRC, and Dr. David Morris, the founder and chairman of Morris Group Canada will join Replenish’s Board of Directors as a director and board advisor, respectively, with Dr. Morris being put forth as a director at Replenish’s next annual shareholder meeting.

Pursuant to the Investment Agreement, SRC will (a) subscribe for 50 million units of the Company (the “Units”) at a price of $0.15 per Unit for gross proceeds of $7.5 million (the “Equity Investment”), each Unit will consist of one common share of the Company (a “Common Share”) and one-half of one common share purchase warrant (each whole warrant, a “Warrant”), each Warrant will entitle the holder to acquire one Common Share at an exercise price of $0.225 for a period of four years from closing, and (b) purchase a senior secured (second lien) convertible debenture (the “Debenture”) in an aggregate principal amount of $7.5 million (the “Debenture Investment”, and together with the Equity Investment, the “Strategic Investment”). The Debenture will bear fixed interest of 10% per annum, payable quarterly, in cash or Common Shares at the Company’s election, will mature four years from closing, and will be convertible into Common Shares at a price of $0.225 per Common Share.

As part of the Strategic Investment, the parties will enter into a supply agreement (the “Supply Agreement”) for the supply and delivery to Replenish of carbonatite, a calcium, phosphorus, trace-mineral and microbial-rich resource used for its soil-enhancing properties, and an investor rights agreement (the “Investor Rights Agreement”), as described below.

Highlights:

SRC will take an initial 19.9% interest (non-diluted) in Replenish through the $7.5 million Equity Investment, providing Replenish access to key growth capital and a long-term strategic partner.Each Unit includes one-half of a Warrant – 25 million Warrants in aggregate – exercisable at $0.225 for four years from closing, subject to an acceleration provision if the Common Shares trade at or above $0.28 for twenty consecutive trading days, representing potential additional proceeds to the Company of up to approximately $5.63 million for future growth.SRC will invest $7.5 million, pursuant to the Debenture Investment, representing flexible and cost-effective capital during a period of rapid expansion.Aggregate investment proceeds will support a separate 150,000 metric tonne pelletizing facility at the Company’s existing Beiseker property, along with additional storage, load-out and processing infrastructure supporting the existing Beiseker granulation facility and the new Beiseker Pelletization Expansion.The Supply Agreement provides a long-term supply of carbonatite to be incorporated into Replenish’s proprietary regenerative fertilizer products, securing a key input that enhances Replenish’s product line.In connection with the Strategic Investment, Tim Close, CEO of SRC Agrominerals, will be appointed to the Replenish board. Mr. Close brings significant leadership and expertise across capital markets, corporate strategy, operational execution and commercial governance. Mr. Close previously served as CEO of Ag Growth International (“AGI”), a large, publicly traded global leader in storage, handling and blending equipment for the fertilizer, seed, grain and food-processing sectors. During his 10-year tenure, Mr. Close led AGI’s transformation from a regional provider of grain-handling equipment into a global leader in food infrastructure, with revenue growing fivefold during that span. He built and led a high-performing team, strengthened operational execution and advanced the company’s global growth strategy, including overseeing the deployment of more than $700 million of capital across 19 strategic transactions. Dr. David Morris, Director of SRC Agrominerals, will also join the Replenish board as an advisor and will be put forward as a director at Replenish’s next annual shareholder meeting. Dr. Morris is the founder and former Chairman of Morris Group Canada Inc., which provided innovative solutions for the construction and resource sectors across Canada and South America, including modular construction, workforce housing, site services, labour management, and safety training. Dr. Morris brings deep operational expertise at a time when Replenish is moving into significant operational and commercial expansion.

CEO Commentary

     Neil Wiens, CEO, Replenish Nutrients

“This strategic relationship marks a pivotal step in Replenish’s growth strategy,” said Neil Wiens, CEO of Replenish Nutrients. “SRC’s investment gives us the capital to accelerate our Beiseker pelletizing expansion, while our new supply agreement gives Replenish access to a key input for our regenerative fertilizer platform. Beyond the capital, we’re gaining a strategic partner in Tim, David and the SRC team, whose operational and capital markets experience will be a significant asset to Replenish as we scale.”

     Tim Close, CEO, SRC Agrominerals

“Replenish has built a capital-efficient, scalable platform for regenerative fertilizer production, and this investment reflects our confidence in their team and their growth trajectory,” said Tim Close, CEO of SRC Agrominerals. “Pairing Replenish’s manufacturing and distribution capabilities with SRC’s carbonatite reserves creates a compelling opportunity to bring the proven soil health benefits of Spanish River Carbonatite to growers across North America. I look forward to joining the Replenish board and supporting the Company through its next phase of growth.”

Beiseker Pelletization Expansion & Facility Pipeline

The planned owned Beiseker Pelletization Expansion will consist of a separate 150,000 metric tonne pelletizing facility, along with additional storage, load-out and processing infrastructure supporting the existing Beiseker granulation facility and the new Beiseker Pelletization Expansion. The Beiseker Pelletization Expansion is expected to be completed by the first quarter of 2028.

The Company expects annualized production from its existing owned and licensed facilities is made up of the following:

Owned Beiseker granulation facility:                                               24,000 metric tonnesOwned Beiseker colony pelletization facility:                                  12,000 metric tonnesLicensed Farmers Union Enterprises (FUE) pelletization facility:   100,000 metric tonnesLicensed MJ Ag pelletization facility:                                               10,000 metric tonnes

The Beiseker Pelletization Expansion will be on the same site as the Company’s existing Beiseker granulation facility and will have no impact to the current production from the Beiseker granulation facility. Upon completion of the new Beiseker Pelletization Expansion, both facilities will benefit from additional shared storage, processing and load-out infrastructure. These capacity estimates have been prepared by management in good faith based on information available to management as of the date hereof and actual results may differ from these expectations.

Consistent with previous guidance, the Company expects gross margins of the new Beiseker Pelletization Expansion to be 25% to 35%. Replenish expects the new pelletization facility to be completed in the first quarter of 2028.

Strategic Investment

Equity Investment – SRC will subscribe for 50 million Units at a price of $0.15 per Unit for gross proceeds of $7.5 million, each Unit will consist of one Common Share and one-half of one Warrant. Each Warrant will entitle the holder to acquire one Common Share at an exercise price of $0.225 for a period of four years from closing of the Equity Investment, subject to an acceleration provision if the Company’s common shares trade at or above $0.28 for twenty consecutive trading days, in accordance with the terms of the warrant certificate governing the Warrants.

Debenture Investment – SRC will also purchase the Debenture in an aggregate principal amount of $7.5 million. The Debenture will bear fixed interest of 10% per annum, payable quarterly, in cash or Common Shares at the Company’s election, will mature four years from closing of the Debenture Investment, and will be convertible into Common Shares at a price of $0.225 per Common Share.

Proceeds from the Strategic Investment shall be applied to the Beiseker Pelletization Expansion, which is expected to be completed in the first quarter of 2028, working capital, inventory purchases, debt repayment, and general corporate purposes.

Closing of the Equity Investment is expected to occur on or about July 24, 2026 and closing of the Debenture Investment is expected to occur on or about August 14, 2026. In accordance with applicable securities laws, the Units and the Debenture will be subject to a hold period expiring four months and one day following the date of issuance. Closing of the Equity Investment and the Debenture Investment is subject to certain customary conditions, including the receipt of all necessary consents, regulatory approvals and the approval of the Canadian Securities Exchange.

Supply Agreement

On closing of the Equity Investment, Replenish and SRC will enter into the Supply Agreement for the supply and delivery to Replenish of carbonatite, a calcium, phosphorus, trace-mineral and microbial-rich resource used for its soil-enhancing properties. Pursuant to the Supply Agreement, Replenish has agreed to purchase a minimum specified quantity per year of carbonatite over a 10-year period, and has agreed to ensure its products contain a minimum specified percentage of carbonatite, subject to product efficacy optimization. Payment terms for the initial volumes are $1 million upon execution of the Supply Agreement.

     About Carbonatite

Carbonatite is a carbonate-rich igneous rock formed from volcanic activity. The Spanish River deposit is distinguished by high concentrations of loosely bonded calcium, phosphorus, potassium, and magnesium, along with trace rare earth elements — and, notably, without the radioactive or toxic heavy metals found in many other carbonatite deposits worldwide.

What makes the mineral agriculturally valuable is its reactivity: its fragile primary mineral structure breaks down quickly once applied to soil, releasing nutrients directly into the root zone rather than remaining chemically locked in rock. In its natural setting, this process has visibly transformed the surrounding landscape — the deposit has saturated the local water table with calcium, phosphorus, and potassium, producing decades of exceptional forest growth around the site.

That same effect has been documented repeatedly in independent and field research. A Wilfrid Laurier University study1 found that SRC raises and stabilizes soil pH, more than doubles beneficial soil microbe populations, supports mycorrhizal fungi, and increases seed weight and crop yield at recommended application rates. Trials2 on wheat, soybeans, and cucumbers have shown statistically significant gains in root and shoot biomass, and soybean trials recorded a marked increase in nitrogen-fixing root nodules. In a multi-year Norfolk Soil and Crop Improvement Association trial3 on asparagus, SRC-treated plots produced 75% greater root mass, brix (sugar/nutrient) readings nearly double the control plots (12–13% vs. 7–8%), and a 10%+ yield increase — with no supplemental fertilizer. A test plot4 at Kerr Farms in Chatham, Ontario, a carbonatite application suppressed aluminum toxicity in soil by 78% while increasing plant calcium uptake by over 200% within five weeks, alongside improved crop density, weed suppression, and overall soil tilth and microbial activity.

Collectively, this body of evidence positions carbonatite as a natural, reactive mineral platform for regenerative soil fertility — restoring soil chemistry, rebuilding microbial ecosystems, and improving nutrient uptake without reliance on synthetic inputs.

Investor Rights Agreement

On closing of the Equity Investment, Replenish and SRC will enter into the Investor Rights Agreement. Pursuant to the Investor Rights Agreement, SRC will have the right to nominate one director to Replenish’s board of directors and the right to participate in future equity issuances of the Company to maintain SRC’s pro rata equity interest on the terms set out in the Investor Rights Agreement. Following closing of the Debenture Investment, SRC will have the right to nominate two directors to Replenish’s board of directors.

Following the closing of the Equity Investment, SRC CEO, Tim Close, will join Replenish’s board of directors, and SRC Director, Dr. David Morris, will join the Replenish board as an advisor until he is put forward as a director at Replenish’s next annual shareholder meeting.

About SRC Agrominerals

SRC is a privately-owned Canadian company and the owner of Spanish River Carbonatite reserves — a mineral deposit located outside of Sudbury, Ontario. SRC has spent 15 years commercializing the deposit, with its flagship product — Spanish River Carbonatite (SRC) — now OMRI and ProCert-listed for organic use and applied across hundreds of thousands of acres in row crops, vegetables, fruit, vineyards, landscaping, and environmental remediation.

About Replenish Nutrients

Replenish Nutrients manufactures and sells proprietary fertilizer products containing essential macro and micro nutrients and biological material while using a proprietary zero-waste manufacturing process. Replenish Nutrients is a wholly-owned subsidiary of Replenish Nutrients Holding Corp. (CSE: ERTH) (OTC: VVIVF). To learn more about Replenish visit our website at www.replenishnutrients.com.

For additional information, please contact:

Replenish Nutrients Investor Relations
Email: info@replenishnutrients.com

Sophic Capital
Sean Peasgood
Email: sean@sophiccapital.com

Notes

The fact sheets for carbonatite can be viewed here:

(1)

srcagrominerals.ca/fact-sheets

(2)

srcagrominerals.ca/a%26l-biological-report

(3)

srcagrominerals.ca/fact-sheets

(4)

srcagrominerals.ca/fact-sheets

Cautionary Note Regarding Forward-Looking Information

This press release contains “forward-looking information” within the meaning of applicable Canadian securities legislation. Forward-looking information includes, but is not limited to, statements regarding: the completion, timing and terms of the $15 million Strategic Investment by SRC, including the closing of the $7.5 million Equity Investment and the $7.5 million Debenture Investment on or about July 24, 2026 and August 14, 2026, respectively, and the conditions to such closings, including the receipt of all necessary consents and regulatory approvals, including the approval of the Canadian Securities Exchange; the potential exercise of the Warrants, including the anticipated additional proceeds to the Company of up to approximately $5.63 million; the anticipated use of proceeds from the Strategic Investment, including the Beiseker Pelletization Expansion, working capital, inventory purchases, debt repayment and general corporate purposes; the anticipated timing for completion of the Beiseker Pelletization Expansion, its expected annual production capacity of 150,000 metric tonnes, and its expected gross margins of approximately 25% to 35%; the anticipated appointment of Tim Close and Dr. David Morris to the Replenish board of directors, the timing of those appointments, and the anticipated benefits of SRC’s board representation and governance rights, including SRC’s right under the Investor Rights Agreement to nominate two directors and to participate in future equity issuances to maintain its pro rata equity interest; the terms, duration and anticipated benefits of the 10-year Supply Agreement with SRC, including the incorporation of carbonatite into Replenish’s regenerative fertilizer products; the anticipated agronomic, soil health, crop yield and product-differentiation benefits of incorporating carbonatite into Replenish’s products, including as referenced in third-party research and field trial results; SRC’s initial 19.9% (non-diluted) equity interest in the Company and the potential for further dilution to existing shareholders; and the Company’s plans and opportunity to build a scalable regenerative fertilizer platform through strategic partnerships of this kind.

Forward-looking information is based on the beliefs, estimates and opinions of management as of the date such statements are made and involves a number of assumptions, including: the Strategic Investment will close on the anticipated terms and timing; all required regulatory and exchange approvals will be obtained; the Investor will fulfill its subscription and funding commitments; the Beiseker Pelletization Expansion will be completed on time; anticipated production capacity and gross margins will be achieved; the Supply Agreement will be executed and performed as contemplated; the anticipated agronomic and product benefits will be realized; key personnel will be appointed to the board of directors as expected; and the Company will have sufficient working capital to execute its growth plans.

These forward-looking statements also involve known and unknown risks, uncertainties and other factors that may cause the actual results, level of activity, performance or achievements of the Company to be materially different from those expressed or implied by such information, including, but not limited to: risks that the Strategic Investment does not close on the anticipated terms, timing, or at all, or that one or both tranches fail to close; risks related to shareholder and regulatory (including CSE) approval of the transaction; dilution to existing shareholders from the Equity Investment, Warrant exercise, and Debenture conversion; risks that the anticipated board appointments do not occur as contemplated or that governance changes affect the Company’s strategic direction; risks that the Supply Agreement does not deliver the anticipated commercial or product benefits, or that SRC is unable to fulfill its supply obligations; risks associated with reliance on a single or limited number of suppliers of carbonatite; risks that the anticipated agronomic, soil health, or product-differentiation benefits of carbonatite are not realized or cannot be substantiated, including because such benefits are based in part on third-party research not independently verified by the Company; risks associated with the commissioning, construction and ramp-up of the Beiseker Pelletization Expansion, including construction delays or cost overruns; risks that anticipated timelines, production volumes, or gross margins for the Beiseker Pelletization Expansion are not achieved; risks related to fertilizer commodity pricing and demand; risks related to the Company’s ability to raise additional capital and to maintain or expand its credit facilities; risks related to the Company’s going concern status; general business, economic, competitive, geopolitical and social uncertainties; regulatory risks; and the other risk factors disclosed in the Company’s public disclosure, which can be found under the Company’s profile on SEDAR+ at www.sedarplus.ca. Readers are cautioned that the foregoing list of risk factors is not exhaustive.

There can be no assurance that such information will prove to be accurate, as actual results and future events could differ materially from those anticipated. Accordingly, readers should not place undue reliance on forward-looking information. The forward-looking information contained in this press release is made as of the date hereof, and the Company does not undertake any obligation to update or revise any forward-looking information, whether as a result of new information, future events or otherwise, except as required by applicable securities laws.

Certain information contained in this press release regarding carbonatite, including statements regarding its composition, properties, agronomic benefits and referenced research and field trial results, has been obtained from third-party sources believed by the Company to be reliable. While such information is believed to be accurate, it has not been independently verified by the Company, and neither the Company nor its officers or directors makes any representation as to the accuracy or completeness of such third-party information.

Neither the Canadian Securities Exchange nor its Market Regulator (as that term is defined in the policies of the Canadian Securities Exchange) accepts responsibility for the adequacy or accuracy of this release.

SOURCE Replenish Nutrients Holding Corp.

Continue Reading
Click to comment

Leave a Reply

Your email address will not be published. Required fields are marked *

Technology

Lumeris Partners With Schmitt-Thompson Clinical Content to Advance Tom™ Symptom-Checking Capability with Evidence-Based Telehealth Triage Guidance

Published

on

By

Partnership strengthens AI-powered symptom checking with trusted clinical content to support more consistent patient guidance and care navigation

CAMBRIDGE, Mass., and CHANDLER, Ariz., July 21, 2026 /PRNewswire/ — Lumeris, a leader in healthcare technology and services, and Schmitt-Thompson Clinical Content (STCC), the leading provider of telehealth triage guidelines and medical call center decision support information in North America, today announced a partnership to integrate STCC’s evidence-based clinical triage content into the symptom-checking capability within Tom™, Lumeris’ AI-powered Primary Care as a Service platform.

The partnership represents the next evolution of Tom’s ability to help care teams extend access, improve patient engagement and deliver more proactive support for individuals with complex health needs. By incorporating STCC’s clinical guidance, Tom’s symptom-checking capability provides healthcare organizations with a stronger clinical foundation for helping patients navigate symptoms between primary care visits while supporting more timely, informed interventions.

Patients with chronic conditions and other complex health needs frequently experience new symptoms, medication concerns or health-related questions between scheduled in-person primary care appointments. Without timely guidance from providers, they may delay care or seek treatment in higher-acuity settings that may not be necessary. Tom’s symptom-checking capability provides an accessible first point of contact, enabling patients and caregivers to report symptoms, ask health-related questions and receive support through natural, conversational interactions while helping care teams identify individuals who may require additional clinical attention.

The integration of STCC’s clinical content strengthens the guidance behind Tom’s symptom-checking experience, helping healthcare organizations deliver more standardized, evidence-based responses to symptom-based questions. By combining conversational patient engagement with trusted clinical decision support, organizations can improve consistency across care settings while helping care teams efficiently assess patient needs and determine appropriate next steps.

“One of the biggest challenges in caring for high-risk populations is making sure patients have access to the right support at the right time,” said Dr. David Carmouche, chief medical and commercial officer, Lumeris. “This partnership strengthens Tom’s role as an active member of the care team by combining conversational patient engagement with trusted clinical guidance. Together, we’re helping organizations deliver more consistent symptom assessment, streamline clinical workflows and support safer, more timely interventions.”

Following each symptom-checking interaction, Tom generates a structured summary along with recommended prioritization guidance to help care teams quickly assess patient needs and determine the most appropriate next actions. The capability complements clinical workflows rather than replaces them, allowing organizations to extend support beyond traditional care settings while maintaining appropriate clinical oversight.

The partnership further advances Lumeris’ vision for Tom as an intelligent extension of the primary care team, combining AI-powered patient engagement, evidence-based clinical guidance and care team workflows to help healthcare organizations improve access, enhance patient experiences and deliver more proactive, coordinated care.

“We’re excited to partner with Lumeris to bring our gold-standard clinical triage guidance to the Tom platform,” said Patty Maynard, chief operating officer, STCC. “Together, we’re enabling healthcare organizations to deliver symptom-checking experiences that combine conversational technology with evidence-based clinical decision support, helping patients receive more consistent guidance while supporting care teams with trusted recommendations they can confidently act on.”

About Lumeris
Lumeris is a leader in healthcare technology and services advancing the future of primary care through Tom, its AI-powered Primary Care as a Service platform designed to function as a proactive member of the care team embedded directly in clinical workflows. Tom autonomously supports best next actions that help providers expand capacity, improve patient access, and reduce administrative burden while enabling more personalized, scalable care delivery. Built on more than two decades of primary care and value-based care experience, Tom reflects Lumeris’ deep experience supporting health systems and physician organizations nationwide and operating Essence Healthcare, its leading Medicare Advantage plan. Founded in 2010, Lumeris is headquartered in St. Louis and Cambridge, Massachusetts. The company employs more than 1,200 engineers, clinicians, and healthcare specialists. Learn more at Lumeris.com.

About Schmitt-Thompson Clinical Content
Schmitt-Thompson Clinical Content (STCC) is the leading source of telehealth triage guidelines and medical call center decision support information in North America. STCC provides the most comprehensive triage and advice content, spanning the continuum of delivery: After Hours, used by hospitals, health systems and insurance companies and Office Hours, used in practices and clinics. Schmitt-Thompson Clinical Content is the ‘gold standard’ in telephone triage, offering evidence-based, efficient and time-tested decision support. It is used by more than 400 health systems and health plans and an additional 10,000 physician practices. Learn more: http://www.stcc-triage.com.

View original content to download multimedia:https://www.prnewswire.com/news-releases/lumeris-partners-with-schmitt-thompson-clinical-content-to-advance-tom-symptom-checking-capability-with-evidence-based-telehealth-triage-guidance-302829780.html

SOURCE Lumeris

Continue Reading

Technology

NorthRock Partners Expands Minneapolis Presence with Addition of Kowalski Financial, Strengthening National Growth Strategy

Published

on

By

The partnership expands NorthRock’s Personal Office® model in its hometown of Minneapolis while bringing additional expertise and resources to Kowalski Financial’s clients.

MINNEAPOLIS, July 21, 2026 /PRNewswire/ — NorthRock Partners (NorthRock), a financial advice firm redefining the wealth management experience through its Personal Office® model, announced today that Kowalski Financial (Kowalski) has joined NorthRock. The partnership brings over $200 million in assets under management (AUM) and five team members, strengthening NorthRock’s growing presence in Minneapolis, MN.

Headquartered in Minneapolis, NorthRock has grown into a national advisory firm by expanding what a single client relationship can include. Its Personal Office® model builds a dedicated, customized team around each client to coordinate investments, tax, estate planning, insurance, legal, business services, and philanthropy in one place, staying alongside clients as their lives change. Each firm that joins NorthRock adds depth to that team and extends the model to more families.

Kowalski Financial brings an experienced team, a strong commitment to client relationships, and a shared belief in delivering personalized, long-term financial advice. Through this partnership, Kowalski advisors will gain access to the full depth of NorthRock’s Personal Office® specialists, expanding the advice and resources available to their clients.

“From the first conversations with Marc and the Kowalski team, it was clear they care deeply about their clients and about doing things the right way,” said Cam Rosenow, Head of Growth at NorthRock Partners. “That matters to us. This partnership is a strong fit because it brings together a team with real client relationships, a shared advice-first mindset, and the ability to plug into the depth of NorthRock’s Personal Office® model. We’re excited to welcome them into our Minneapolis office and build together from here.”

Founded in 2019, Kowalski Financial provided multidisciplinary financial planning services, including estate planning and tax services. The firm adds a talented group of advisors and professionals who share NorthRock’s commitment to helping clients navigate both financial decisions and life transitions.

“Joining NorthRock represents an exciting opportunity for our team and the clients we serve,” said Marc Kowalski, CEO at Kowalski Financial. “We have always believed that great advice starts with understanding the full picture of a client’s goals, values, and priorities. NorthRock’s Personal Office® model provides an expanded platform of expertise and resources that will allow us to continue delivering the personalized guidance our clients expect while enhancing the services available to them.”

The addition of Kowalski Financial reinforces the continued momentum behind NorthRock’s growth strategy and Personal Office® model. As advisors and families seek more coordinated approaches to wealth management, NorthRock continues to partner with firms that share its commitment to delivering customized, comprehensive advice. Furthermore, the Kowalski team will relocate to NorthRock Partners’ offices in downtown Minneapolis.

About NorthRock Partners
NorthRock Partners is a financial advice company serving more than 6,000 clients and managing over $12 billion in assets. For more than 30 years, NorthRock has placed clients’ financial and life needs at the center through its Personal Office® model. This integrated approach builds a dedicated, customized team around each advisor and enables them to coordinate all aspects of a client’s life, including investments, tax, insurance, estate, legal, business strategies, lifestyle, and philanthropy. NorthRock is recognized as one of Barron’s Top 100 RIAs in the United States. The firm also offers specialized divisions that include NorthRock X for athletes and entertainers and Foundation X for philanthropic advice and services. Learn more at www.northrockpartners.com.

Disclosures:
All investment advisory and Personal Office® services are provided by and through NorthRock Partners LLC, an SEC registered investment adviser. SEC registration does not imply a certain level of skill or training.

NorthRock Partners was recognized in Barron’s Top 100 RIAs in September 2025. The ranking was determined by Barron’s using criteria including AUM growth, employee growth, proprietary data and the number of advisors considered for evaluation. NorthRock Partners did not pay a fee to be considered for or included in the ranking. Additional information regarding the ranking methodology is available from Barron’s.

View original content to download multimedia:https://www.prnewswire.com/news-releases/northrock-partners-expands-minneapolis-presence-with-addition-of-kowalski-financial-strengthening-national-growth-strategy-302830371.html

SOURCE NorthRock Partners

Continue Reading

Technology

Compass, Inc. to Announce Second Quarter Results on August 4

Published

on

By

NEW YORK, July 21, 2026 /PRNewswire/ — Compass, Inc., d/b/a Compass International Holdings (the “Company”) (NYSE: COMP), a global real estate services company, announced its second quarter 2026 financial results will be released after market close on Tuesday, August 4, 2026. The Company will host a conference call and webcast to discuss its results that afternoon at 5:00 p.m. ET / 2:00 p.m. PT.

Call details are as follows:

The conference call and shareholder presentation will be accessible online via the Company’s Investor Relations website, https://investors.compass.com.You can also register in advance to access the live conference call at: Compass Inc. Q2 26 Earnings Conference Call.An audio recording of the conference call will be available for replay shortly after the call, for 90 days. To access the replay and shareholder presentation, visit the Events and Presentations section of the Company’s Investor Relations website.

About Compass, Inc., d/b/a Compass International Holdings

Compass, Inc., d/b/a Compass International Holdings (the “Company”) (NYSE: COMP) is a global real estate services company with a presence in every major U.S. city and approximately 120 countries and territories. Compass International Holdings serves millions of buyers and sellers through a portfolio of some of the most recognized and iconic brands: @properties, Better Homes and Gardens® Real Estate, CENTURY 21®, Christie’s International Real Estate, Coldwell Banker®, Compass, Corcoran®, ERA®, and Sotheby’s International Realty®. Every day, the Company empowers a global network of more than 300,000 real estate professionals in its owned-brokerage and franchise business to grow and deliver exceptional service to consumers.

The Company empowers real estate professionals to streamline operations and seamlessly guide clients through every phase of residential and commercial transactions, leveraging powerful tools, including its modern technology platform. In addition to brokerage services, Compass International Holdings offers integrated services, such as mortgage, title, insurance, escrow, and relocation.

The Company uses its Investor Relations website, https://investors.compass.com, to disclose information that may be of interest or material to its investors and to comply with disclosure obligations under Regulation FD. Accordingly, investors should monitor the Company’s Investor Relations website and follow the Company’s press releases, SEC filings, public conference calls, webcasts, and social media.

Investor Relations Contact
Soham Bhonsle
soham.bhonsle@compass.com

Media Contact
Devin Daly Huerta
Devin.daly@compass.com

View original content to download multimedia:https://www.prnewswire.com/news-releases/compass-inc-to-announce-second-quarter-results-on-august-4-302830274.html

SOURCE Compass, Inc.

Continue Reading

Trending